TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06849258: A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms

Sponsor: Rivermark Medical · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 215 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,357,200

Rescue Site Savings

+$1,560,400

Unlock Full NCT06849258 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06849258 Rescue Dossier →